Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence

[1]  A. Kapoor,et al.  Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting. , 2018, Current oncology.

[2]  C. Porta,et al.  CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups , 2017, Annals of Oncology.

[3]  Dang M. Tran,et al.  Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States. , 2017, Journal of managed care & specialty pharmacy.

[4]  A. Kapoor,et al.  First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. , 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[5]  T. Delea,et al.  Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. , 2016, Current oncology.

[6]  C. Beauchemin,et al.  A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada , 2016, Journal of medical economics.

[7]  T. Delea,et al.  Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. , 2015, Journal of managed care & specialty pharmacy.

[8]  C. Porta,et al.  Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Kiss,et al.  Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.

[10]  Y. Najjar,et al.  A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. , 2014, European journal of cancer.

[11]  T. Bathala,et al.  Adult UrologyOncology: Adrenal/Renal/Upper Tract/BladderClinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules , 2014 .

[12]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[13]  R. Breau,et al.  Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[14]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, International Journal of Technology Assessment in Health Care.

[15]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, BMJ.

[16]  William Hollingworth,et al.  Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[17]  C. Barrios,et al.  Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma , 2012, Cancer.

[18]  I. Chabot,et al.  How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  David Cella,et al.  Elicitation of health state utilities in metastatic renal cell carcinoma , 2010, Current medical research and opinion.

[20]  W. Linehan,et al.  Molecular diagnosis and therapy of kidney cancer. , 2010, Annual review of medicine.

[21]  H. Verheul,et al.  Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? , 2009, Angiogenesis.

[22]  C. Charbonneau,et al.  Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.

[23]  Xu Zhang,et al.  Erratum to "A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model" [Computer Methods and Programs in Biomedicine 88 (2007) 95-101] , 2008, Comput. Methods Programs Biomed..

[24]  Xu Zhang,et al.  A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model , 2007, Comput. Methods Programs Biomed..

[25]  S. Verma,et al.  Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis , 2006, Supportive Care in Cancer.

[26]  W. Marston Linehan,et al.  Genetic Basis of Cancer of the Kidney , 2004, Clinical Cancer Research.

[27]  S. Campbell,et al.  Metastatic renal cell carcinoma , 2003, Current treatment options in oncology.

[28]  A. Kiss,et al.  Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.